NasdaqGS:TEMLife Sciences
Tempus AI (TEM) Is Up 8.5% After FDA Clearance for Advanced Cardiac MRI Mapping – Has the Bull Case Changed?
Tempus AI recently received FDA 510(k) clearance for its updated Tempus Pixel platform, enabling T1 and T2 inline mapping for enhanced cardiac MR image analysis using artificial intelligence.
This advancement allows clinicians to generate precise, quantitative tissue assessments directly from raw MRI data, providing new diagnostic capabilities even on scanners without native mapping support.
We'll explore how this recent regulatory milestone and Tempus Pixel's expanded functionality could...